Luminex Corporation Appoints Frank Reeves Chief Financial Officer and James Schepp Vice President of Sales and Marketing

Apr 19, 2001, 01:00 ET from Luminex Corporation

    AUSTIN, Texas, April 19 /PRNewswire Interactive News Release/ --
 Luminex Corporation (Nasdaq: LMNX) announced today that Frank J. Reeves has
 joined the company as Executive Vice President, Treasurer and Chief Financial
 Officer and that James E. Schepp has joined the company as Vice President of
 Sales and Marketing.  Mr. Reeves succeeds James Persky, who is retiring.
     Mr. Reeves joins Luminex from PricewaterhouseCoopers LLP, with whom he
 worked for the past sixteen years.  Reeves co-led the development of the
 technology practice for the Austin office of Coopers and Lybrand, which later
 merged with Pricewaterhouse, and was responsible for significant growth in
 that organization and its practice.
     "As CFO, Frank will continue to drive the company financially and
 strategically into the future," said Mark Chandler, Chairman and CEO of the
 company.  "He brings numerous years of diverse public accounting experience
 which should prove invaluable to Luminex.  We are grateful for the many
 contributions James Persky made to the company.  James was instrumental in
 developing our strong financial foundation and business model, which Frank
 will continue to build upon in the years to come."
     Mr. Schepp joins Luminex from Beckman Coulter where he worked for the past
 24 years, most recently serving as Vice President of European Commercial
 Operations.  His division was responsible for over $500 million in annual
 sales, including all Beckman Coulter product lines.  Schepp also directed the
 national and international business integration of Beckman Coulter following
 Beckman's acquisition of Coulter.  Mr. Schepp brings over 20 years of sales
 and marketing experience in the hospital, diagnostic and life sciences markets
 to Luminex.
     "Jim is a highly accomplished executive with progressive ideas and years
 of success in the sales, marketing and commercial operations arenas.  We are
 very pleased with his decision to join our management team.  Jim's principal
 focus will be in driving our sales and marketing strategies as we continue to
 broaden our business and expand our partner base in the US and
 internationally," commented Dr. Chandler.
 
     Luminex Corporation develops, manufactures and markets proprietary
 biological testing technologies with applications throughout the life sciences
 industry.  The company's LabMAP(TM) system is an open-architecture,
 multi-analyte technology platform that delivers fast, accurate and
 cost-effective bioassay results to markets as diverse as pharmaceutical drug
 discovery, clinical diagnostics and biomedical research. The LabMAP system is
 sold worldwide and is already in use in leading research laboratories as well
 as major pharmaceutical, diagnostic and biotechnology companies. Further
 information on Luminex Corporation or LabMAP can be obtained at
 http://www.luminexcorp.com.
 
     Statements made in this press release that express Luminex's or
 management's intentions, plans, beliefs, expectations or predictions of future
 events are forward-looking statements.  The words "believe," "expect,"
 "intend," "estimate," "anticipate," "will" and similar expressions are
 intended to further identify such forward-looking statements.  It is important
 to note that the company's actual results or performance could differ
 materially from those anticipated or projected in such forward-looking
 statements.  Factors that could cause Luminex's actual results or performance
 to differ materially include risks and uncertainties relating to market demand
 and acceptance of Luminex's products, the company's dependence on strategic
 partners for development and distribution of products, competition, Luminex's
 ability to scale-up manufacturing operations, potential shortages of
 components and the timing of regulatory approvals, as well as the risks
 discussed under the heading "Factors That May Affect Future Results'' in
 Luminex's annual report on Form 10-K for the year ended December 31, 2000, as
 filed with the Securities and Exchange Commission.  The forward-looking
 statements contained herein represent the judgment of Luminex as of the date
 of this press release, and Luminex expressly disclaims any intent, obligation
 or undertaking to update or revise such forward-looking statements to reflect
 any change in Luminex's expectations with regard thereto or any change in
 events, conditions or circumstances on which any such statements are based.
 
     CONTACT:  Mark B. Chandler, Ph.D., Chairman, President and CEO of
               Luminex Corporation, 512-219-8020
 
                      MAKE YOUR OPINION COUNT - Click Here
                http://tbutton.prnewswire.com/prn/11690X17313868
 
 

SOURCE Luminex Corporation
    AUSTIN, Texas, April 19 /PRNewswire Interactive News Release/ --
 Luminex Corporation (Nasdaq: LMNX) announced today that Frank J. Reeves has
 joined the company as Executive Vice President, Treasurer and Chief Financial
 Officer and that James E. Schepp has joined the company as Vice President of
 Sales and Marketing.  Mr. Reeves succeeds James Persky, who is retiring.
     Mr. Reeves joins Luminex from PricewaterhouseCoopers LLP, with whom he
 worked for the past sixteen years.  Reeves co-led the development of the
 technology practice for the Austin office of Coopers and Lybrand, which later
 merged with Pricewaterhouse, and was responsible for significant growth in
 that organization and its practice.
     "As CFO, Frank will continue to drive the company financially and
 strategically into the future," said Mark Chandler, Chairman and CEO of the
 company.  "He brings numerous years of diverse public accounting experience
 which should prove invaluable to Luminex.  We are grateful for the many
 contributions James Persky made to the company.  James was instrumental in
 developing our strong financial foundation and business model, which Frank
 will continue to build upon in the years to come."
     Mr. Schepp joins Luminex from Beckman Coulter where he worked for the past
 24 years, most recently serving as Vice President of European Commercial
 Operations.  His division was responsible for over $500 million in annual
 sales, including all Beckman Coulter product lines.  Schepp also directed the
 national and international business integration of Beckman Coulter following
 Beckman's acquisition of Coulter.  Mr. Schepp brings over 20 years of sales
 and marketing experience in the hospital, diagnostic and life sciences markets
 to Luminex.
     "Jim is a highly accomplished executive with progressive ideas and years
 of success in the sales, marketing and commercial operations arenas.  We are
 very pleased with his decision to join our management team.  Jim's principal
 focus will be in driving our sales and marketing strategies as we continue to
 broaden our business and expand our partner base in the US and
 internationally," commented Dr. Chandler.
 
     Luminex Corporation develops, manufactures and markets proprietary
 biological testing technologies with applications throughout the life sciences
 industry.  The company's LabMAP(TM) system is an open-architecture,
 multi-analyte technology platform that delivers fast, accurate and
 cost-effective bioassay results to markets as diverse as pharmaceutical drug
 discovery, clinical diagnostics and biomedical research. The LabMAP system is
 sold worldwide and is already in use in leading research laboratories as well
 as major pharmaceutical, diagnostic and biotechnology companies. Further
 information on Luminex Corporation or LabMAP can be obtained at
 http://www.luminexcorp.com.
 
     Statements made in this press release that express Luminex's or
 management's intentions, plans, beliefs, expectations or predictions of future
 events are forward-looking statements.  The words "believe," "expect,"
 "intend," "estimate," "anticipate," "will" and similar expressions are
 intended to further identify such forward-looking statements.  It is important
 to note that the company's actual results or performance could differ
 materially from those anticipated or projected in such forward-looking
 statements.  Factors that could cause Luminex's actual results or performance
 to differ materially include risks and uncertainties relating to market demand
 and acceptance of Luminex's products, the company's dependence on strategic
 partners for development and distribution of products, competition, Luminex's
 ability to scale-up manufacturing operations, potential shortages of
 components and the timing of regulatory approvals, as well as the risks
 discussed under the heading "Factors That May Affect Future Results'' in
 Luminex's annual report on Form 10-K for the year ended December 31, 2000, as
 filed with the Securities and Exchange Commission.  The forward-looking
 statements contained herein represent the judgment of Luminex as of the date
 of this press release, and Luminex expressly disclaims any intent, obligation
 or undertaking to update or revise such forward-looking statements to reflect
 any change in Luminex's expectations with regard thereto or any change in
 events, conditions or circumstances on which any such statements are based.
 
     CONTACT:  Mark B. Chandler, Ph.D., Chairman, President and CEO of
               Luminex Corporation, 512-219-8020
 
                      MAKE YOUR OPINION COUNT - Click Here
                http://tbutton.prnewswire.com/prn/11690X17313868
 
 SOURCE  Luminex Corporation